Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis

Esther J. Aspinall; Stephen Corson; Joseph S. Doyle; Jason Grebely; Sharon Hutchinson; Gregory J. Dore; David Goldberg; Margaret E. Hellard

doi:10.1093/cid/cit306

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis

Esther J. Aspinall
, Stephen Corson
, Joseph S. Doyle
, Jason Grebely
, Sharon Hutchinson
, Gregory J. Dore
, David Goldberg
, Margaret E. Hellard

SHLS School Office

Research output: Contribution to journal › Article › peer-review

280 Citations (Scopus)

Abstract

Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection.

Original language	English
Pages (from-to)	S80-89
Number of pages	10
Journal	Clinical Infectious Diseases
Volume	53
Issue number	Suppl 2
DOIs	https://doi.org/10.1093/cid/cit306
Publication status	Published - Aug 2013

Keywords

hepatitis C virus
drug users
sustained virologic response
virus infection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Documents and Links

10.1093/cid/cit306

Cite this

@article{337c48e3b8a4481599fad7928fc8e4f2,

title = "Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis",

abstract = "Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection.",

keywords = "hepatitis C virus, drug users, sustained virologic response, virus infection",

author = "Aspinall, \{Esther J.\} and Stephen Corson and Doyle, \{Joseph S.\} and Jason Grebely and Sharon Hutchinson and Dore, \{Gregory J.\} and David Goldberg and Hellard, \{Margaret E.\}",

note = "Note: title changed on publication (previous title provided by SHLS was 'Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis'). Made changes and validated by Library for REF. ET 26-11-13",

year = "2013",

month = aug,

doi = "10.1093/cid/cit306",

language = "English",

volume = "53",

pages = "S80--89",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "Suppl 2",

}

TY - JOUR

T1 - Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis

AU - Aspinall, Esther J.

AU - Corson, Stephen

AU - Doyle, Joseph S.

AU - Grebely, Jason

AU - Hutchinson, Sharon

AU - Dore, Gregory J.

AU - Goldberg, David

AU - Hellard, Margaret E.

N1 - Note: title changed on publication (previous title provided by SHLS was 'Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis'). Made changes and validated by Library for REF. ET 26-11-13

PY - 2013/8

Y1 - 2013/8

N2 - Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection.

AB - Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection.

KW - hepatitis C virus

KW - drug users

KW - sustained virologic response

KW - virus infection

UR - https://www.scopus.com/pages/publications/84880984985

U2 - 10.1093/cid/cit306

DO - 10.1093/cid/cit306

M3 - Article

AN - SCOPUS:84880984985

SN - 1058-4838

VL - 53

SP - S80-89

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - Suppl 2

ER -

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis

Abstract

Keywords

UN SDGs

Documents and Links

Other files and links

Fingerprint

Cite this